Abstract | RATIONALE: OBJECTIVES: METHODS: Healthy participants (n = 10) with/out current drug use/ pain conditions completed this within-subject, double-blind, placebo-controlled, randomized outpatient study. Nine 8-h sessions were completed during which dronabinol (0, 2.5, 5 mg, p.o.) was administered 1 h before oxycodone (0, 5, 10 mg, p.o.) for a total of 9 test conditions. Outcomes included sensory threshold and tolerance from four experimental pain models (cold pressor, pressure algometer, hot thermode, cold hyperalgesia), along with participant- and observer-rated, performance and physiological effects. RESULTS: CONCLUSIONS: This study indicates that dronabinol did not enhance the analgesic effects of oxycodone and increased abuse- and impairment-related subjective effects. These data suggest that dronabinol may not be an effective or appropriate opioid adjuvant; it could potentially increase opioid dose requirements, while increasing psychoactive opioid effects.
|
Authors | Shanna Babalonis, Michelle R Lofwall, Paul A Sloan, Paul A Nuzzo, Laura C Fanucchi, Sharon L Walsh |
Journal | Psychopharmacology
(Psychopharmacology (Berl))
Vol. 236
Issue 11
Pg. 3341-3352
(Nov 2019)
ISSN: 1432-2072 [Electronic] Germany |
PMID | 31201479
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Analgesics, Opioid
- Cannabinoid Receptor Agonists
|
Topics |
- Adolescent
- Adult
- Analgesia
(methods, psychology)
- Analgesics, Opioid
(pharmacology, therapeutic use)
- Cannabinoid Receptor Agonists
(pharmacology, therapeutic use)
- Cross-Over Studies
- Diagnostic Self Evaluation
- Double-Blind Method
- Female
- Healthy Volunteers
- Humans
- Male
- Middle Aged
- Pain
(drug therapy, psychology)
- Pain Measurement
(drug effects, methods, psychology)
- Psychomotor Performance
(drug effects, physiology)
- Young Adult
|